Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZENITH-CKD: Zibotentan plus dapagliflozin vs dapagliflozin in chronic kidney disease
jRCT2041200106Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2021
- Modality
- Small Molecules
01
Overview
Randomised trial of zibotentan and dapagliflozin in chronic kidney disease (CKD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change in log-transformed urinary albumin-to-creatinine ratio (UACR) from baseline to Week 12. Started Apr 2021; status: completed.
02
Drugs
zibotentandapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2041200106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041200106.